APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pulmonary Drugs Market Analysis and Forecast 2026-2032

22 December 2025219 pages

Choose your research edition.

Industry ResearchPulmonary Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Pulmonary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Pulmonary Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pulmonary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pulmonary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pulmonary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pulmonary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pulmonary Drugs include Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, GlaxoSmithKline Plc., Glenmark Pharmaceuticals Ltd., AbbVie Inc., AstraZeneca Plc., Zambon Company S.p.A and Wellona Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pulmonary Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pulmonary Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Pulmonary Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pulmonary Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pulmonary Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pulmonary Drugs revenue, projected growth trends, production technology, application and end-user industry.

Pulmonary Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.

Sanofi SA

Novartis AG

GlaxoSmithKline Plc.

Glenmark Pharmaceuticals Ltd.

AbbVie Inc.

AstraZeneca Plc.

Zambon Company S.p.A

Wellona Pharma

Vertex Pharmaceuticals Inc.

Sumitomo Pharma Co. Ltd.

Merck Sharp & Dohme Limited

Medisol Lifescience Pvt. Ltd.

Meda Pharmaceuticals

Mallinckrodt Pharmaceuticals Plc.

Lupin Ltd.

Grifols, S.A.

F. Hoffmann La Roche Ltd.

Circassia Pharmaceuticals Plc.

Cipla Ltd.

Cheisi Farmaceutici S.p.A

Celon Pharma SA

Boehringer Ingelheim

Aurobindo Pharma Ltd.

Alaxia SAS

Aerogen Pharma Ltd.

Abbott Laboratories

Pulmonary Drugs Segment by Type

Antihistamines

Inhaled Corticosteroids

Vasodilators

Long Acting Beta-2 Agonists

Others

Pulmonary Drugs Segment by Application

Asthma & COPD

Cystic Fibrosis

Pulmonary Arterial Hypertension

Allergic Rhinitis

Others

Pulmonary Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pulmonary Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pulmonary Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antihistamines Major Player Table 3. Inhaled Corticosteroids Major Player Table 4. Vasodilators Major Player Table 5. Long Acting Beta-2 Agonists Major Player Table 6. Others Major Player Table 7. Global Pulmonary Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Asthma & COPD Major Player Table 9. Cystic Fibrosis Major Player Table 10. Pulmonary Arterial Hypertension Major Player Table 11. Allergic Rhinitis Major Player Table 12. Others Major Player Table 13. Pulmonary Drugs Industry Trends Table 14. Pulmonary Drugs Industry Drivers Table 15. Pulmonary Drugs Industry Opportunities and Challenges Table 16. Pulmonary Drugs Industry Restraints Table 17. Global Pulmonary Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Pulmonary Drugs Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Pulmonary Drugs Market Share by Region (2021-2026) Table 20. Global Pulmonary Drugs Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Pulmonary Drugs Market Share by Region (2027-2032) Table 22. Global Pulmonary Drugs Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Pulmonary Drugs Revenue Market Share by Players (2021-2026) Table 24. Global Pulmonary Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Pulmonary Drugs Key Players Headquarters & Area Served Table 26. Global Pulmonary Drugs Players, Product Type & Application Table 27. Global Pulmonary Drugs Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Pulmonary Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Pulmonary Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Pulmonary Drugs Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Pulmonary Drugs Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Pulmonary Drugs Revenue Market Share by Type (2021-2026) Table 34. Global Pulmonary Drugs Revenue Market Share by Type (2027-2032) Table 35. Global Pulmonary Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Pulmonary Drugs Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Pulmonary Drugs Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Pulmonary Drugs Revenue Market Share by Application (2021-2026) Table 39. Global Pulmonary Drugs Revenue Market Share by Application (2027-2032) Table 40. Teva Pharmaceutical Industries Ltd. Company Information Table 41. Teva Pharmaceutical Industries Ltd. Business Overview Table 42. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio Table 44. Teva Pharmaceutical Industries Ltd. Recent Development Table 45. Sanofi SA Company Information Table 46. Sanofi SA Business Overview Table 47. Sanofi SA Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sanofi SA Pulmonary Drugs Product Portfolio Table 49. Sanofi SA Recent Development Table 50. Novartis AG Company Information Table 51. Novartis AG Business Overview Table 52. Novartis AG Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novartis AG Pulmonary Drugs Product Portfolio Table 54. Novartis AG Recent Development Table 55. GlaxoSmithKline Plc. Company Information Table 56. GlaxoSmithKline Plc. Business Overview Table 57. GlaxoSmithKline Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio Table 59. GlaxoSmithKline Plc. Recent Development Table 60. Glenmark Pharmaceuticals Ltd. Company Information Table 61. Glenmark Pharmaceuticals Ltd. Business Overview Table 62. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio Table 64. Glenmark Pharmaceuticals Ltd. Recent Development Table 65. AbbVie Inc. Company Information Table 66. AbbVie Inc. Business Overview Table 67. AbbVie Inc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. AbbVie Inc. Pulmonary Drugs Product Portfolio Table 69. AbbVie Inc. Recent Development Table 70. AstraZeneca Plc. Company Information Table 71. AstraZeneca Plc. Business Overview Table 72. AstraZeneca Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. AstraZeneca Plc. Pulmonary Drugs Product Portfolio Table 74. AstraZeneca Plc. Recent Development Table 75. Zambon Company S.p.A Company Information Table 76. Zambon Company S.p.A Business Overview Table 77. Zambon Company S.p.A Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Zambon Company S.p.A Pulmonary Drugs Product Portfolio Table 79. Zambon Company S.p.A Recent Development Table 80. Wellona Pharma Company Information Table 81. Wellona Pharma Business Overview Table 82. Wellona Pharma Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Wellona Pharma Pulmonary Drugs Product Portfolio Table 84. Wellona Pharma Recent Development Table 85. Vertex Pharmaceuticals Inc. Company Information Table 86. Vertex Pharmaceuticals Inc. Business Overview Table 87. Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio Table 89. Vertex Pharmaceuticals Inc. Recent Development Table 90. Sumitomo Pharma Co. Ltd. Company Information Table 91. Sumitomo Pharma Co. Ltd. Business Overview Table 92. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio Table 94. Sumitomo Pharma Co. Ltd. Recent Development Table 95. Merck Sharp & Dohme Limited Company Information Table 96. Merck Sharp & Dohme Limited Business Overview Table 97. Merck Sharp & Dohme Limited Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio Table 99. Merck Sharp & Dohme Limited Recent Development Table 100. Medisol Lifescience Pvt. Ltd. Company Information Table 101. Medisol Lifescience Pvt. Ltd. Business Overview Table 102. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio Table 104. Medisol Lifescience Pvt. Ltd. Recent Development Table 105. Meda Pharmaceuticals Company Information Table 106. Meda Pharmaceuticals Business Overview Table 107. Meda Pharmaceuticals Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Meda Pharmaceuticals Pulmonary Drugs Product Portfolio Table 109. Meda Pharmaceuticals Recent Development Table 110. Mallinckrodt Pharmaceuticals Plc. Company Information Table 111. Mallinckrodt Pharmaceuticals Plc. Business Overview Table 112. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 114. Mallinckrodt Pharmaceuticals Plc. Recent Development Table 115. Lupin Ltd. Company Information Table 116. Lupin Ltd. Business Overview Table 117. Lupin Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Lupin Ltd. Pulmonary Drugs Product Portfolio Table 119. Lupin Ltd. Recent Development Table 120. Grifols, S.A. Company Information Table 121. Grifols, S.A. Business Overview Table 122. Grifols, S.A. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Grifols, S.A. Pulmonary Drugs Product Portfolio Table 124. Grifols, S.A. Recent Development Table 125. F. Hoffmann La Roche Ltd. Company Information Table 126. F. Hoffmann La Roche Ltd. Business Overview Table 127. F. Hoffmann La Roche Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio Table 129. F. Hoffmann La Roche Ltd. Recent Development Table 130. Circassia Pharmaceuticals Plc. Company Information Table 131. Circassia Pharmaceuticals Plc. Business Overview Table 132. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 134. Circassia Pharmaceuticals Plc. Recent Development Table 135. Cipla Ltd. Company Information Table 136. Cipla Ltd. Business Overview Table 137. Cipla Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Cipla Ltd. Pulmonary Drugs Product Portfolio Table 139. Cipla Ltd. Recent Development Table 140. Cheisi Farmaceutici S.p.A Company Information Table 141. Cheisi Farmaceutici S.p.A Business Overview Table 142. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio Table 144. Cheisi Farmaceutici S.p.A Recent Development Table 145. Celon Pharma SA Company Information Table 146. Celon Pharma SA Business Overview Table 147. Celon Pharma SA Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. Celon Pharma SA Pulmonary Drugs Product Portfolio Table 149. Celon Pharma SA Recent Development Table 150. Boehringer Ingelheim Company Information Table 151. Boehringer Ingelheim Business Overview Table 152. Boehringer Ingelheim Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 153. Boehringer Ingelheim Pulmonary Drugs Product Portfolio Table 154. Boehringer Ingelheim Recent Development Table 155. Aurobindo Pharma Ltd. Company Information Table 156. Aurobindo Pharma Ltd. Business Overview Table 157. Aurobindo Pharma Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 158. Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio Table 159. Aurobindo Pharma Ltd. Recent Development Table 160. Alaxia SAS Company Information Table 161. Alaxia SAS Business Overview Table 162. Alaxia SAS Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 163. Alaxia SAS Pulmonary Drugs Product Portfolio Table 164. Alaxia SAS Recent Development Table 165. Aerogen Pharma Ltd. Company Information Table 166. Aerogen Pharma Ltd. Business Overview Table 167. Aerogen Pharma Ltd. Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 168. Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio Table 169. Aerogen Pharma Ltd. Recent Development Table 170. Abbott Laboratories Company Information Table 171. Abbott Laboratories Business Overview Table 172. Abbott Laboratories Pulmonary Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 173. Abbott Laboratories Pulmonary Drugs Product Portfolio Table 174. Abbott Laboratories Recent Development Table 175. North America Pulmonary Drugs Revenue by Type (2021-2026) & (US$ Million) Table 176. North America Pulmonary Drugs Revenue by Type (2027-2032) & (US$ Million) Table 177. North America Pulmonary Drugs Revenue by Application (2021-2026) & (US$ Million) Table 178. North America Pulmonary Drugs Revenue by Application (2027-2032) & (US$ Million) Table 179. North America Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. North America Pulmonary Drugs Revenue by Country (2021-2026) & (US$ Million) Table 181. North America Pulmonary Drugs Revenue by Country (US$ Million) & (2027-2032) Table 182. Europe Pulmonary Drugs Revenue by Type (2021-2026) & (US$ Million) Table 183. Europe Pulmonary Drugs Revenue by Type (2027-2032) & (US$ Million) Table 184. Europe Pulmonary Drugs Revenue by Application (2021-2026) & (US$ Million) Table 185. Europe Pulmonary Drugs Revenue by Application (2027-2032) & (US$ Million) Table 186. Europe Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 187. Europe Pulmonary Drugs Revenue by Country (2021-2026) & (US$ Million) Table 188. Europe Pulmonary Drugs Revenue by Country (US$ Million) & (2027-2032) Table 189. China Pulmonary Drugs Revenue by Type (2021-2026) & (US$ Million) Table 190. China Pulmonary Drugs Revenue by Type (2027-2032) & (US$ Million) Table 191. China Pulmonary Drugs Revenue by Application (2021-2026) & (US$ Million) Table 192. China Pulmonary Drugs Revenue by Application (2027-2032) & (US$ Million) Table 193. Asia Pulmonary Drugs Revenue by Type (2021-2026) & (US$ Million) Table 194. Asia Pulmonary Drugs Revenue by Type (2027-2032) & (US$ Million) Table 195. Asia Pulmonary Drugs Revenue by Application (2021-2026) & (US$ Million) Table 196. Asia Pulmonary Drugs Revenue by Application (2027-2032) & (US$ Million) Table 197. Asia Pulmonary Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 198. Asia Pulmonary Drugs Revenue by Region (US$ Million) & (2021-2026) Table 199. Asia Pulmonary Drugs Revenue by Region (US$ Million) & (2027-2032) Table 200. SAMEA Pulmonary Drugs Revenue by Type (2021-2026) & (US$ Million) Table 201. SAMEA Pulmonary Drugs Revenue by Type (2027-2032) & (US$ Million) Table 202. SAMEA Pulmonary Drugs Revenue by Application (2021-2026) & (US$ Million) Table 203. SAMEA Pulmonary Drugs Revenue by Application (2027-2032) & (US$ Million) Table 204. SAMEA Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. SAMEA Pulmonary Drugs Revenue by Country (2021-2026) & (US$ Million) Table 206. SAMEA Pulmonary Drugs Revenue by Country (US$ Million) & (2027-2032) Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. Pulmonary Drugs Image Figure 2. Global Pulmonary Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antihistamines Image Figure 5. Inhaled Corticosteroids Image Figure 6. Vasodilators Image Figure 7. Long Acting Beta-2 Agonists Image Figure 8. Others Image Figure 9. Global Pulmonary Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Pulmonary Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 11. Asthma & COPD Image Figure 12. Cystic Fibrosis Image Figure 13. Pulmonary Arterial Hypertension Image Figure 14. Allergic Rhinitis Image Figure 15. Others Image Figure 16. Global Pulmonary Drugs Market Size (US$ Million) & (2021-2032) Figure 17. Global Pulmonary Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Pulmonary Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Pulmonary Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Pulmonary Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pulmonary Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Pulmonary Drugs Revenue Market Share by Type (2021-2032) Figure 24. Global Pulmonary Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pulmonary Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Pulmonary Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Pulmonary Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Pulmonary Drugs Revenue Share by Type (2021-2032) Figure 29. North America Pulmonary Drugs Revenue Share by Application (2021-2032) Figure 30. North America Pulmonary Drugs Revenue Share by Country (2021-2032) Figure 31. United States Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Pulmonary Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Pulmonary Drugs Revenue Share by Type (2021-2032) Figure 36. Europe Pulmonary Drugs Revenue Share by Application (2021-2032) Figure 37. Europe Pulmonary Drugs Revenue Share by Country (2021-2032) Figure 38. Germany Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Pulmonary Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Pulmonary Drugs Revenue Share by Type (2021-2032) Figure 48. China Pulmonary Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Pulmonary Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Pulmonary Drugs Revenue Share by Type (2021-2032) Figure 51. Asia Pulmonary Drugs Revenue Share by Application (2021-2032) Figure 52. Asia Pulmonary Drugs Revenue Share by Region (2021-2032) Figure 53. Japan Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Pulmonary Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Pulmonary Drugs Revenue Share by Type (2021-2032) Figure 61. SAMEA Pulmonary Drugs Revenue Share by Application (2021-2032) Figure 62. SAMEA Pulmonary Drugs Revenue Share by Country (2021-2032) Figure 63. Brazil Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Pulmonary Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Antihistamines
  • Inhaled Corticosteroids
  • Vasodilators
  • Long Acting Beta-2 Agonists
  • Others
Applications
  • Asthma & COPD
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension
  • Allergic Rhinitis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Glenmark Pharmaceuticals Ltd.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Zambon Company S.p.A
  • Wellona Pharma
  • Vertex Pharmaceuticals Inc.
  • Sumitomo Pharma Co. Ltd.
  • Merck Sharp & Dohme Limited
  • Medisol Lifescience Pvt. Ltd.
  • Meda Pharmaceuticals
  • Mallinckrodt Pharmaceuticals Plc.
  • Lupin Ltd.
  • Grifols, S.A.
  • F. Hoffmann La Roche Ltd.
  • Circassia Pharmaceuticals Plc.
  • Cipla Ltd.
  • Cheisi Farmaceutici S.p.A
  • Celon Pharma SA
  • Boehringer Ingelheim
  • Aurobindo Pharma Ltd.
  • Alaxia SAS
  • Aerogen Pharma Ltd.
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pulmonary Drugs Market by Type
  3. 1.2.1 Global Pulmonary Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antihistamines
  5. 1.2.3 Inhaled Corticosteroids
  6. 1.2.4 Vasodilators
  7. 1.2.5 Long Acting Beta-2 Agonists
  8. 1.2.6 Others
  9. 1.3 Pulmonary Drugs Market by Application
  10. 1.3.1 Global Pulmonary Drugs Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Asthma & COPD
  12. 1.3.3 Cystic Fibrosis
  13. 1.3.4 Pulmonary Arterial Hypertension
  14. 1.3.5 Allergic Rhinitis
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Pulmonary Drugs Market Dynamics
  1. 2.1 Pulmonary Drugs Industry Trends
  2. 2.2 Pulmonary Drugs Industry Drivers
  3. 2.3 Pulmonary Drugs Industry Opportunities and Challenges
  4. 2.4 Pulmonary Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pulmonary Drugs Market Perspective (2021-2032)
  2. 3.2 Global Pulmonary Drugs Growth Trends by Region
  3. 3.2.1 Global Pulmonary Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pulmonary Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Pulmonary Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pulmonary Drugs Revenue by Players
  2. 4.1.1 Global Pulmonary Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Pulmonary Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pulmonary Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pulmonary Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pulmonary Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Pulmonary Drugs Players, Product Type & Application
  8. 4.5 Global Pulmonary Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pulmonary Drugs Market CR5 and HHI
  11. 4.6.3 2025 Pulmonary Drugs Tier 1, Tier 2, and Tier 3
5 Pulmonary Drugs Market Size by Type
  1. 5.1 Global Pulmonary Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pulmonary Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Pulmonary Drugs Revenue Market Share by Type (2021-2032)
6 Pulmonary Drugs Market Size by Application
  1. 6.1 Global Pulmonary Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pulmonary Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Pulmonary Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd.
  2. 7.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 7.2 Sanofi SA
  8. 7.2.1 Sanofi SA Company Information
  9. 7.2.2 Sanofi SA Business Overview
  10. 7.2.3 Sanofi SA Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi SA Pulmonary Drugs Product Portfolio
  12. 7.2.5 Sanofi SA Recent Developments
  13. 7.3 Novartis AG
  14. 7.3.1 Novartis AG Company Information
  15. 7.3.2 Novartis AG Business Overview
  16. 7.3.3 Novartis AG Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis AG Pulmonary Drugs Product Portfolio
  18. 7.3.5 Novartis AG Recent Developments
  19. 7.4 GlaxoSmithKline Plc.
  20. 7.4.1 GlaxoSmithKline Plc. Company Information
  21. 7.4.2 GlaxoSmithKline Plc. Business Overview
  22. 7.4.3 GlaxoSmithKline Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio
  24. 7.4.5 GlaxoSmithKline Plc. Recent Developments
  25. 7.5 Glenmark Pharmaceuticals Ltd.
  26. 7.5.1 Glenmark Pharmaceuticals Ltd. Company Information
  27. 7.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
  28. 7.5.3 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio
  30. 7.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  31. 7.6 AbbVie Inc.
  32. 7.6.1 AbbVie Inc. Company Information
  33. 7.6.2 AbbVie Inc. Business Overview
  34. 7.6.3 AbbVie Inc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Inc. Pulmonary Drugs Product Portfolio
  36. 7.6.5 AbbVie Inc. Recent Developments
  37. 7.7 AstraZeneca Plc.
  38. 7.7.1 AstraZeneca Plc. Company Information
  39. 7.7.2 AstraZeneca Plc. Business Overview
  40. 7.7.3 AstraZeneca Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca Plc. Pulmonary Drugs Product Portfolio
  42. 7.7.5 AstraZeneca Plc. Recent Developments
  43. 7.8 Zambon Company S.p.A
  44. 7.8.1 Zambon Company S.p.A Company Information
  45. 7.8.2 Zambon Company S.p.A Business Overview
  46. 7.8.3 Zambon Company S.p.A Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Zambon Company S.p.A Pulmonary Drugs Product Portfolio
  48. 7.8.5 Zambon Company S.p.A Recent Developments
  49. 7.9 Wellona Pharma
  50. 7.9.1 Wellona Pharma Company Information
  51. 7.9.2 Wellona Pharma Business Overview
  52. 7.9.3 Wellona Pharma Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Wellona Pharma Pulmonary Drugs Product Portfolio
  54. 7.9.5 Wellona Pharma Recent Developments
  55. 7.10 Vertex Pharmaceuticals Inc.
  56. 7.10.1 Vertex Pharmaceuticals Inc. Company Information
  57. 7.10.2 Vertex Pharmaceuticals Inc. Business Overview
  58. 7.10.3 Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio
  60. 7.10.5 Vertex Pharmaceuticals Inc. Recent Developments
  61. 7.11 Sumitomo Pharma Co. Ltd.
  62. 7.11.1 Sumitomo Pharma Co. Ltd. Company Information
  63. 7.11.2 Sumitomo Pharma Co. Ltd. Business Overview
  64. 7.11.3 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio
  66. 7.11.5 Sumitomo Pharma Co. Ltd. Recent Developments
  67. 7.12 Merck Sharp & Dohme Limited
  68. 7.12.1 Merck Sharp & Dohme Limited Company Information
  69. 7.12.2 Merck Sharp & Dohme Limited Business Overview
  70. 7.12.3 Merck Sharp & Dohme Limited Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio
  72. 7.12.5 Merck Sharp & Dohme Limited Recent Developments
  73. 7.13 Medisol Lifescience Pvt. Ltd.
  74. 7.13.1 Medisol Lifescience Pvt. Ltd. Company Information
  75. 7.13.2 Medisol Lifescience Pvt. Ltd. Business Overview
  76. 7.13.3 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio
  78. 7.13.5 Medisol Lifescience Pvt. Ltd. Recent Developments
  79. 7.14 Meda Pharmaceuticals
  80. 7.14.1 Meda Pharmaceuticals Company Information
  81. 7.14.2 Meda Pharmaceuticals Business Overview
  82. 7.14.3 Meda Pharmaceuticals Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Meda Pharmaceuticals Pulmonary Drugs Product Portfolio
  84. 7.14.5 Meda Pharmaceuticals Recent Developments
  85. 7.15 Mallinckrodt Pharmaceuticals Plc.
  86. 7.15.1 Mallinckrodt Pharmaceuticals Plc. Company Information
  87. 7.15.2 Mallinckrodt Pharmaceuticals Plc. Business Overview
  88. 7.15.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  90. 7.15.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
  91. 7.16 Lupin Ltd.
  92. 7.16.1 Lupin Ltd. Company Information
  93. 7.16.2 Lupin Ltd. Business Overview
  94. 7.16.3 Lupin Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Lupin Ltd. Pulmonary Drugs Product Portfolio
  96. 7.16.5 Lupin Ltd. Recent Developments
  97. 7.17 Grifols, S.A.
  98. 7.17.1 Grifols, S.A. Company Information
  99. 7.17.2 Grifols, S.A. Business Overview
  100. 7.17.3 Grifols, S.A. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Grifols, S.A. Pulmonary Drugs Product Portfolio
  102. 7.17.5 Grifols, S.A. Recent Developments
  103. 7.18 F. Hoffmann La Roche Ltd.
  104. 7.18.1 F. Hoffmann La Roche Ltd. Company Information
  105. 7.18.2 F. Hoffmann La Roche Ltd. Business Overview
  106. 7.18.3 F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio
  108. 7.18.5 F. Hoffmann La Roche Ltd. Recent Developments
  109. 7.19 Circassia Pharmaceuticals Plc.
  110. 7.19.1 Circassia Pharmaceuticals Plc. Company Information
  111. 7.19.2 Circassia Pharmaceuticals Plc. Business Overview
  112. 7.19.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  114. 7.19.5 Circassia Pharmaceuticals Plc. Recent Developments
  115. 7.20 Cipla Ltd.
  116. 7.20.1 Cipla Ltd. Company Information
  117. 7.20.2 Cipla Ltd. Business Overview
  118. 7.20.3 Cipla Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Cipla Ltd. Pulmonary Drugs Product Portfolio
  120. 7.20.5 Cipla Ltd. Recent Developments
  121. 7.21 Cheisi Farmaceutici S.p.A
  122. 7.21.1 Cheisi Farmaceutici S.p.A Company Information
  123. 7.21.2 Cheisi Farmaceutici S.p.A Business Overview
  124. 7.21.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio
  126. 7.21.5 Cheisi Farmaceutici S.p.A Recent Developments
  127. 7.22 Celon Pharma SA
  128. 7.22.1 Celon Pharma SA Company Information
  129. 7.22.2 Celon Pharma SA Business Overview
  130. 7.22.3 Celon Pharma SA Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Celon Pharma SA Pulmonary Drugs Product Portfolio
  132. 7.22.5 Celon Pharma SA Recent Developments
  133. 7.23 Boehringer Ingelheim
  134. 7.23.1 Boehringer Ingelheim Company Information
  135. 7.23.2 Boehringer Ingelheim Business Overview
  136. 7.23.3 Boehringer Ingelheim Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Boehringer Ingelheim Pulmonary Drugs Product Portfolio
  138. 7.23.5 Boehringer Ingelheim Recent Developments
  139. 7.24 Aurobindo Pharma Ltd.
  140. 7.24.1 Aurobindo Pharma Ltd. Company Information
  141. 7.24.2 Aurobindo Pharma Ltd. Business Overview
  142. 7.24.3 Aurobindo Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio
  144. 7.24.5 Aurobindo Pharma Ltd. Recent Developments
  145. 7.25 Alaxia SAS
  146. 7.25.1 Alaxia SAS Company Information
  147. 7.25.2 Alaxia SAS Business Overview
  148. 7.25.3 Alaxia SAS Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Alaxia SAS Pulmonary Drugs Product Portfolio
  150. 7.25.5 Alaxia SAS Recent Developments
  151. 7.26 Aerogen Pharma Ltd.
  152. 7.26.1 Aerogen Pharma Ltd. Company Information
  153. 7.26.2 Aerogen Pharma Ltd. Business Overview
  154. 7.26.3 Aerogen Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio
  156. 7.26.5 Aerogen Pharma Ltd. Recent Developments
  157. 7.27 Abbott Laboratories
  158. 7.27.1 Abbott Laboratories Company Information
  159. 7.27.2 Abbott Laboratories Business Overview
  160. 7.27.3 Abbott Laboratories Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  161. 7.27.4 Abbott Laboratories Pulmonary Drugs Product Portfolio
  162. 7.27.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Pulmonary Drugs Revenue (2021-2032)
  2. 8.2 North America Pulmonary Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Pulmonary Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Pulmonary Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Pulmonary Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Pulmonary Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Pulmonary Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Pulmonary Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Pulmonary Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Pulmonary Drugs Revenue by Country
  11. 8.6.1 North America Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pulmonary Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Pulmonary Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pulmonary Drugs Revenue (2021-2032)
  2. 9.2 Europe Pulmonary Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pulmonary Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pulmonary Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Pulmonary Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pulmonary Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pulmonary Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pulmonary Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Pulmonary Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pulmonary Drugs Revenue by Country
  11. 9.6.1 Europe Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pulmonary Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pulmonary Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pulmonary Drugs Revenue (2021-2032)
  2. 10.2 China Pulmonary Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Pulmonary Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Pulmonary Drugs Revenue by Type (2027-2032)
  5. 10.3 China Pulmonary Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Pulmonary Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Pulmonary Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Pulmonary Drugs Revenue by Application (2027-2032)
  9. 10.5 China Pulmonary Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pulmonary Drugs Revenue (2021-2032)
  2. 11.2 Asia Pulmonary Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pulmonary Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pulmonary Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Pulmonary Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pulmonary Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pulmonary Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pulmonary Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Pulmonary Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pulmonary Drugs Revenue by Country
  11. 11.6.1 Asia Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pulmonary Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pulmonary Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pulmonary Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Pulmonary Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pulmonary Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pulmonary Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pulmonary Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pulmonary Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pulmonary Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pulmonary Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pulmonary Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pulmonary Drugs Revenue by Country
  11. 12.6.1 SAMEA Pulmonary Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pulmonary Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pulmonary Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst